Literature DB >> 15850483

Morphological and growth altering effects of Cisplatin in C. albicans using fluorescence microscopy.

Chandrasekhar Kesavan1, Malathi Raghunathan, Natarajan Ganesan.   

Abstract

Changes in morphology and growth curve of Candida albicans in response to treatment by Cisplatin has been studied using fluorescence staining with ethidium bromide. Treatment with Cisplatin was found to markedly inhibit hyphae and ovoid growth as revealed by ethidium bromide staining of drug treated cells. These changes were concomitant with inhibitory effects on the growth curve with respect to untreated cells. Presence of Cisplatin not only caused suppression in the limiting values in the growth curve, but also caused a slight left shift in the EC50 values. Some of the ovoid cells undergoing poisoning with cisplatin were found to be unusually enlarged before undergoing their natural fate thus suggesting formation of similar cytotoxic end products with DNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15850483      PMCID: PMC1090548          DOI: 10.1186/1476-0711-4-7

Source DB:  PubMed          Journal:  Ann Clin Microbiol Antimicrob        ISSN: 1476-0711            Impact factor:   3.944


Introduction

Candida albicans is a yeast pathogen that causes mild, chronic, superficial systemic infections in immunocompromised and cancer patients [1-3]. Research, worldwide is broadly focused on 1) search of new targets in C. alibcans, 2) Screening inhibitory activities with therapeutic agents, and 3) designing or modifying novel agents, to overcome treatment resistance [4]. C. alibcans has been shown to harbor a self splicing group-I intron in the nuclear 25s rRNA genes [5]. Presence of this gene in C. alibcans, but not in the human genome, suggests that splicing inhibitors could potentially act as alternate targets in controlling the proliferation of fungal pathogens. Recent screening studies using disk diffusion have shown that cis-diamminedichloro platinum (Cisplatin), a well-established antitumor agent, inhibits the growth of C. alibcans at lower concentrations [6]. Despite its prevalent use in cancer treatment, very little work has been done [7-10] to document the effects of Cisplatin and related metal complexes in controlling the proliferation behavior of C. alibcans. With the molecular mechanisms remaining largely unknown, this provided us a basis to study the effects of Cisplatin treatment on the morphology and growth curve of C. alibcans. Morphological changes in Candida can be followed by direct fluorescence staining with suitable dyes to selectively visualize different parts/aspects of cellular activities [11-13]. Though the use of Ethidium Bromide for fluorescence staining is well known, there is no report to show the use of this technique in studying the morphology of Candida, especially in response to treatment with anticancer agents such as Cisplatin. Herein, we report the morphological changes of C. alibcans in response to cisplatin using fluorescence microscopy with ethidium bromide staining.

Materials and methods

Media and Inoculums

Yeast isolates (clinical strains) were obtained from patients, Royapettah Hospital, Chennai. Sub-cultured isolates were maintained in Sabouraud dextrose agar (B.B.L, Cockeysville, MD) at 1–5 × 106 CFU/10 ml media. 30 μl of each sample (log phase) was used for slide preparation to study the morphological changes.

Drug preparation

A 2 mg/ml stock of Cisplatin (TNDPL, Chennai) was prepared in sterile Millipore water. Stock was diluted to 60 μg/10 ml culture for treatment purposes.

Staining

Ethidium bromide staining was performed using a freshly prepared stock of ethidium bromide (1 mg/ml water) from which 50 μl/100 ml concentration was used for staining the slides. Gram staining was performed from commercially available kits as per instructions.

Morphological studies using Fluorescence Microscopy

30 μl of cultured C. alibcans (Drug treated/non-treated cells) was taken and spread over the clean glass slide and dried at 37°C for 5 minutes. Slides were dipped into the EtBr staining solution for 30–40 seconds followed by immersion in water for 15–20 seconds to remove excess stain. Gram staining was performed in parallel on a similar set of slides to validate the results. Both the set of slides were viewed using NFM under the 100× magnification.

Results and Discussion

Treatment of C. alibcans with Cisplatin was found to markedly inhibit hyphae and ovoid growth (Fig. 2) as revealed by ethidium bromide staining of drug treated cells. This was in contrast to the controls showing markedly branched hyphae, with budding characteristics (Fig. 1). The ovoid cells of Cisplatin treated C. alibcans showed an increased uptake of the ethidium bromide stain (red color) in contrast to the untreated counterparts (yellowish orange), thus pointing to drug induced poisoning and death of treated cells. These changes were concomitant with inhibitory effects on the growth curve with respect to untreated cells (Fig. 3). Presence of Cisplatin not only caused suppression in the limiting growth values but caused a slight left shift in the EC50 values, which remains to be studied further. Some of the ovoid cells undergoing poisoning with cisplatin were found to be unusually enlarged before undergoing their natural fate (Fig. 2). This is known to be one of the typical effects of poisoning with cisplatin in case of tumor cell lines as well thus suggesting formation of similar cytotoxic end products [14]. Cisplatin in water forms a diaqua species of Pt+2 due to the fast leaving Cl- ions. This could lead further to host of reactions in the cytoplasm before forming end products with DNA. It is also possible that cisplatin exerts its activity through other secondary response mechanisms. Further studies using RT-PCR will elucidate 1) the role of the binding affinity of cis-DDP to certain RNA species in cytotoxicity against C. albicans, for example, group-I intron ribozyme, known in many human diseases causing pathogens and a potential target site for therapeutic agents. 2) Whether cis-DDP inhibits the C. alibcans growth through penetration into the cell or some secondary response.
Figure 2

Photograph showing morphology of Candida albicans in the presence or absence of cisplatin (6 ug/ml), stained with ethidium bromide and gram stain.

Figure 1

Photograph showing morphology of Candida albicans in the absence of cisplatin (6 ug/ml), stained with ethidium bromide and gram stain.

Figure 3

Growth curve of in the presence/absence of Cisplatin (6 μg/ml). Curve fitting of data points was performed using non-linear regression(sigmoidal curve): GraphPad Prism Version 3.02.

Photograph showing morphology of Candida albicans in the absence of cisplatin (6 ug/ml), stained with ethidium bromide and gram stain. Photograph showing morphology of Candida albicans in the presence or absence of cisplatin (6 ug/ml), stained with ethidium bromide and gram stain. Growth curve of in the presence/absence of Cisplatin (6 μg/ml). Curve fitting of data points was performed using non-linear regression(sigmoidal curve): GraphPad Prism Version 3.02.
  14 in total

1.  Can antitumor platinum compounds be effective against Candida albicans?--A screening assay using disk diffusion method.

Authors:  K Chandrasekar; J H Shyla; R Malathi
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 2.  Virulence factors of Candida albicans.

Authors:  R A Calderone; W A Fonzi
Journal:  Trends Microbiol       Date:  2001-07       Impact factor: 17.079

3.  Anti-Candida activity of a new platinum derivative.

Authors:  T Watanabe; M Takano; A Ogasawara; T Mikami; T Kobayashi; M Watabe; T Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin.

Authors:  A M Otto; R Paddenberg; S Schubert; H G Mannherz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 5.  Membrane transporters and antifungal drug resistance.

Authors:  V St Georgiev
Journal:  Curr Drug Targets       Date:  2000-11       Impact factor: 3.465

6.  Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition.

Authors:  K E Miletti; M J Leibowitz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Evaluation of the genotoxic spectrum of cisplatin for Candida albicans.

Authors:  A Sarachek; L Henderson; W E Wilkens
Journal:  Microbios       Date:  1992

Review 8.  Gastrointestinal tract in the immunocompromised host: opportunistic infections and other complications.

Authors:  S D Wall; B Jones
Journal:  Radiology       Date:  1992-11       Impact factor: 11.105

9.  Changes in Candida albicans colonization and morphology under influence of voriconazole.

Authors:  Hannelore Bernhardt; M Knoke; J Bernhardt
Journal:  Mycoses       Date:  2003       Impact factor: 4.377

10.  Modification of responses of Candida albicans to cisplatin by membrane damaging antimycotic agents.

Authors:  A Sarachek; L A Henderson
Journal:  Mycoses       Date:  1991 Mar-Apr       Impact factor: 4.377

View more
  2 in total

Review 1.  Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Authors:  Sharon C-A Chen; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

2.  Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans.

Authors:  Madhushree M Routh; Nitin M Chauhan; S Mohan Karuppayil
Journal:  Braz J Microbiol       Date:  2014-01-15       Impact factor: 2.476

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.